Trial Profile
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Tovinontrine (Primary) ; Hydroxycarbamide
- Indications Sickle cell anaemia
- Focus Adverse reactions; Proof of concept
- Sponsors Imara Inc
- 22 Nov 2021 According to an Imara Inc media release, the company expects to present updated 12-month VOC data from this trial at the American Society of Hematology Annual Meeting in December 2021.
- 11 Jun 2021 Results (n-=93) published in the Imara Inc Media Release.
- 11 Jun 2021 According to an Imara Inc media release, data from this trial were presented at the European Hematology Association (EHA) Annual Congress 2021, being held virtually.